Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.56 |
| ▸ | CIT | O14578 | 2/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | PFKFB1 | P16118 | 2/20 | 0.42 |
| ▸ | AS3MT | Q9HBK9 | 2/20 | 0.42 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105378 | 0.86 | SPHK1 (0.57) | SPHK1CITAAK1TAAR1CA12 | |
| SCHEMBL6291030 | 0.83 | LTA4H (0.45) | SPHK1CITSPHK2AAK1LTA4H | |
| SCHEMBL10431761 | 0.82 | SPHK1 (0.56) | SPHK1CITCA12CA1CA2 | |
| SCHEMBL12997448 | 0.82 | SPHK1 (0.60) | SPHK1CITSPHK2LTA4H | |
| SCHEMBL8526953 | 0.81 | SPHK1 (0.55) | SPHK1CITLTA4HTAAR1 | |
| SCHEMBL2311252 | 0.81 | SPHK1 (0.55) | SPHK1CITLTA4HTAAR1 | |
| SCHEMBL8526956 | 0.81 | SPHK1 (0.55) | SPHK1CITLTA4HTAAR1 | |
| SCHEMBL6286723 | 0.80 | LTA4H (0.47) | SPHK1SPHK2AAK1LTA4H | |
| Hydrochloric Acid SCHEMBL20569864 | 0.80 | SPHK1 (0.54) | SPHK1CITLTA4HTAAR1 | |
| SCHEMBL19234512 | 0.79 | SPHK1 (0.69) | SPHK1CITSPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | SPHK1 1494/4885CIT 3573/4885SPHK2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.